These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1526714)

  • 21. [Pre- and post-therapeutic serum concentrations of mucin-like carcinoma-associated antigen in patients with breast cancer].
    Fuith LC; Artner-Dworzak E; Schröcksnadel H; Müller-Holzner E; Daxenbichler G; Heim K
    Gynakol Rundsch; 1989; 29 Suppl 2():397-9. PubMed ID: 2613061
    [No Abstract]   [Full Text] [Related]  

  • 22. [Tumor markers--serologic parameters for monitoring and therapeutic control of cancer patients].
    Birkmayer J
    Wien Med Wochenschr; 1988 Jun; 138(11-12):276-8. PubMed ID: 3176507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benign positive margins after radical prostatectomy means a poor prognosis--con.
    Rubin MA; Montie JE
    Urology; 2005 Feb; 65(2):221-3. PubMed ID: 15708026
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
    Aoyagi Y; Oguro M; Yanagi M; Mita Y; Suda T; Suzuki Y; Hata K; Ichii K; Asakura H
    Cancer; 1996 May; 77(9):1781-6. PubMed ID: 8646674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Oncological follow-up].
    Esser D
    HNO; 2010 Aug; 58(8):747-8. PubMed ID: 20694543
    [No Abstract]   [Full Text] [Related]  

  • 26. [Elevated PSA--what to do?].
    Machemer H; Rohde D
    MMW Fortschr Med; 2008 Oct; 150(44):38-9. PubMed ID: 19024490
    [No Abstract]   [Full Text] [Related]  

  • 27. [Analysis of calcitonin level in the diagnosis and evaluation of the results of the treatment of medullary carcinoma of the thyroid gland].
    Krassowski J; Słowińska-Srzednicka J; Gietka M; Sawicki A; Kokot F; Zgliczyński S
    Pol Tyg Lek; 1989 Aug 7-14; 44(32-33):757-9. PubMed ID: 2641802
    [No Abstract]   [Full Text] [Related]  

  • 28. [Value of blood assay of tumor markers for detecting recurrence of colorectal cancer].
    Pélissier E; Bosset JF; Meneveau N
    Bull Cancer; 1994 Dec; 81(12):1050-6. PubMed ID: 7742592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The value of PSA follow-up in recurrent prostate carcinoma after radical prostatovesiculectomy].
    Trinkler F; Hauri D
    Helv Chir Acta; 1994 Dec; 60(6):1081-5. PubMed ID: 7533147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mucinous carcinoma-associated antigen (MCA) in ovarian cancer].
    Hanzal E; Kölbl H; Gitsch G; Bieglmayer C
    Gynakol Rundsch; 1990; 30 Suppl 1():68-70. PubMed ID: 2079303
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
    Lai IR; Lee WJ; Huang MT; Lin HH
    Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Empirically treating high serum thyroglobulin levels.
    Mazzaferri EL
    J Nucl Med; 2005 Jul; 46(7):1079-88. PubMed ID: 16000275
    [No Abstract]   [Full Text] [Related]  

  • 33. Follow-up care of cancer survivors.
    Galassi A
    Lippincotts Prim Care Pract; 2000; 4(4):359-70; quiz 371-3. PubMed ID: 11261113
    [No Abstract]   [Full Text] [Related]  

  • 34. Tumor markers in patients with relapse of colorectal carcinoma.
    Lipská L; Visokai V; Levý M; Svobodová S; Kormunda S; Fínek J
    Anticancer Res; 2007; 27(4A):1901-5. PubMed ID: 17649792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Diagnostic and prognostic value of CEA and GICA in colo-rectal tumors. A caseload contribution].
    Lasagna B; Balbo G; De Paolis P; Sacchetti M
    Minerva Med; 1990 Nov; 81(11):769-71. PubMed ID: 2255411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunologic tumor diagnosis].
    Schmolke B
    Z Lymphol; 1990 Dec; 14(2):58-61. PubMed ID: 2087871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simultaneous measurement of CA 125, CA 19-9, tissue polypeptide antigen, and immunosuppressive acidic protein to predict recurrence of ovarian cancer.
    Kamiya N; Mizuno K; Kawai M; Kano T; Furuhashi Y; Tomoda Y
    Obstet Gynecol; 1990 Sep; 76(3 Pt 1):417-21. PubMed ID: 2381619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence.
    Marques AR; Teixeira E; Diamond J; Correia H; Santos S; Neto L; Ribeiro M; Miranda A; Passos-Coelho JL
    Breast Cancer Res Treat; 2009 Mar; 114(2):223-32. PubMed ID: 18409061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [MCA and CA 15-3 in the follow-up of patients with breast cancer].
    Hammer J; Track C; Hohenwallner W; Seewald DH; Zoidl JP; Wimmer E
    Strahlenther Onkol; 1992 Feb; 168(2):102-6. PubMed ID: 1542844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Tumor markers in diagnosis of breast cancer].
    Bartel U
    Z Arztl Fortbild (Jena); 1991 Oct; 85(20):1015-21. PubMed ID: 1776283
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.